{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:19:54Z","timestamp":1777418394200,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2003,4]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report a seizure occurring secondary to meperidine treatment despite normal renal and central nervous system (CNS) function, and to provide a review of meperidine's role in pain management, including its use in pancreatitis and sphincter of Oddi dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 55-year-old white woman with a history of sphincter of Oddi dysfunction presented to the emergency department with severe abdominal pain. On admission to the hospital, the serum creatinine level was 0.6 mg\/dL with slightly elevated aspartate aminotransferase of 56 U\/L (normal range 0\u201331) and alanine aminotransferase of 34 U\/L (0\u201331). The patient received repeated and escalating doses of intravenous meperidine, resulting in a generalized seizure on day 4 of hospitalization. The accumulated meperidine dose was 2125 mg. Buprenorphine was substituted in place of meperidine, and the patient had no further reported complications. She was then transferred to a tertiary-care facility for sphincter of Oddi reevaluation. An objective causality assessment revealed the adverse drug event as probable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Despite alternative opioids, meperidine continues to be used in pain management. Meperidine is different from other opioids because its active metabolite, normeperidine, is neurotoxic. Patients with renal insufficiency, liver failure, or CNS dysfunction are at increased risk for adverse drug reactions related to normeperidine accumulation. Due to normeperidine's extended half-life, however, accumulation of normeperidine can occur in any patient receiving repeated doses of meperidine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>This case demonstrates the potential hazards that exist when using meperidine in any patient. Meperidine's inherent risks of both undertreating pain and causing adverse drug reactions should prompt clinicians and health organizations to restrict its use in pain management. This restriction should not make exceptions to meperidine's traditional use in pancreatitis or sphincter of Oddi dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1c108","type":"journal-article","created":{"date-parts":[[2003,3,27]],"date-time":"2003-03-27T13:04:20Z","timestamp":1048770260000},"page":"534-537","source":"Crossref","is-referenced-by-count":20,"title":["Meperidine Misuse in a Patient with Sphincter of Oddi Dysfunction"],"prefix":"10.1177","volume":"37","author":[{"given":"Garrick P","family":"Hubbard","sequence":"first","affiliation":[{"name":"Garrick P Hubbard MD, Internal Medicine Chief Resident, Medical Education Department, Ball Memorial Hospital, Muncie, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly R","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Kelly R Wolfe PharmD, Clinical Pharmacist, Pharmacy Department, Ball Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,4,1]]},"reference":[{"key":"bibr1-aph.1C108","unstructured":"1 Hill CD. Joint commission focuses on pain management. www.jcaho.org\/news+room\/health+care+issues\/jcaho+focuses+on+pain+management.htm (accessed 2002 Nov 20)."},{"key":"bibr2-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410130213"},{"key":"bibr3-aph.1C108","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-86-6-738"},{"key":"bibr4-aph.1C108","unstructured":"4 Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Professional, 2001; 468, 592\u20134."},{"key":"bibr5-aph.1C108","volume-title":"Principles of analgesic use in the treatment of acute pain and cancer pain","year":"1999","edition":"4"},{"key":"bibr6-aph.1C108","volume-title":"Clinical practice guideline for acute pain management: operative or medical procedures and trauma. AHCPR Publication #92-0032","author":"Carr D","year":"1992"},{"key":"bibr7-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr8-aph.1C108","unstructured":"8 McEvoy G, ed. AHFS drug information 2002. Bethesda, MD: American Society of Health-System Pharmacists, 2002: 2060\u20132."},{"key":"bibr9-aph.1C108","volume-title":"Demerol (meperidine hydrochloride)","author":"Prescribing information","year":"1999"},{"key":"bibr10-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1994.tb02815.x"},{"key":"bibr11-aph.1C108","unstructured":"11 Miller RD. Anesthesia. 5th ed. Philadelphia: Churchill Livingstone, 2000: 348\u20139."},{"key":"bibr12-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200007000-00001"},{"key":"bibr13-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200201000-00010"},{"key":"bibr14-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.12.1582"},{"key":"bibr15-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)63125-X"},{"key":"bibr16-aph.1C108","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-1-92"},{"key":"bibr17-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03536.x"},{"key":"bibr18-aph.1C108","first-page":"809","volume-title":"Gastrointestinal and liver disease","author":"Banks P.","year":"1998","edition":"6"},{"key":"bibr19-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1177\/106002809302700106"},{"key":"bibr20-aph.1C108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9592.1998.00743.x"},{"issue":"4","key":"bibr21-aph.1C108","first-page":"66","volume":"16","author":"Vermeulen LC","year":"1997","journal-title":"Pharmacy Pract Manag Q"},{"key":"bibr22-aph.1C108","first-page":"174","volume":"10","author":"Pellegrini JE","year":"1999","journal-title":"CRNA"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1C108","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:06:48Z","timestamp":1777374408000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1C108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1345\/aph.1C108"],"URL":"https:\/\/doi.org\/10.1345\/aph.1c108","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}